Ex Parte van de Winkel - Page 1

                     The opinion in support of the decision being entered today was not written for publication            
                                    and is not binding precedent of the Board                                              

                               UNITED STATES PATENT AND TRADEMARK OFFICE                                                   
                                    BEFORE THE BOARD OF PATENT APPEALS                                                     
                                                AND INTERFERENCES                                                          
                                          Ex parte JAN G. J. van de WINKEL                                                 
                                                 Appeal No. 2005-1504                                                      
                                               Application No. 09/820,099                                                  
                                                       ON BRIEF                                                            

              ELLIS, MILLS and GRIMES, Administrative Patent Judges.                                                       
              ELLIS, Administrative Patent Judge.                                                                          

                                                DECISION ON APPEAL1                                                        
                     This is an appeal pursuant to 35 U.S.C.  134 from the examiner’s final rejection                     
              of claims 1 and 6-12.  Claims 2-5 and 13-25 have been cancelled.                                             
                     Claim 1 is representative of the subject matter on appeal and reads as follows:                       
                     1.   A method for eliminating a target cell or antigen from the circulatory system of                 
                     a subject comprising administering to the subject a complex comprising                                
                     monomeric IgA or a portion thereof that binds to Fc"RI, linked to a second                            
                     portion which specifically binds the target cell or antigen.                                          

                     1This decision supercedes the one mailed on September 21, 2005.                                       

Page:  1  2  3  4  5  6  7  8  9  Next 

Last modified: November 3, 2007